Cue Biopharma shares surge on positive mid-stage study results for CUE-221
Cue Biopharma shares soared 28.9% in premarket trading after the company announced positive results from its mid-stage study for CUE-221 in hives treatment. The company stated that the phase 2 primary and key secondary endpoints were met. Earlier in the month, Cue Biopharma reported that its Q2 revenue more than doubled.
Cue Biopharma shares rose 28.9% to $47.74 in premarket trading after the company reported positive results from a mid-stage study of CUE-221 for hives treatment. The company said the phase 2 primary and key secondary endpoints were met. Earlier this month, CUE's Q2 revenue more than doubled. Up to the previous day's close, the shares were up more than 300% year to date.